Pilot Shows EU Needs A ‘Robust’ Shortage Signaling System for ‘Critical’ Drugs

EU pharma companies see manufacturing and logistics issues as the main cause for supply problems, but are concerned about the costs of investing in and gaining regulatory approval for new or updated production facilities, according to a new report.